The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Thromboangiitis Obliterans

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Thromboangiitis Obliterans


High impact information on Thromboangiitis Obliterans


Chemical compound and disease context of Thromboangiitis Obliterans


Biological context of Thromboangiitis Obliterans


Anatomical context of Thromboangiitis Obliterans


Gene context of Thromboangiitis Obliterans


  1. Cellular sensitivity to collagen in thromboangiitis obliterans. Adar, R., Papa, M.Z., Halpern, Z., Mozes, M., Shoshan, S., Sofer, B., Zinger, H., Dayan, M., Mozes, E. N. Engl. J. Med. (1983) [Pubmed]
  2. Lack of association between the Met196Arg polymorphism in the TNFR2 gene and autoimmune diseases accompanied by vasculitis including SLE in Japanese. Takahashi, M., Hashimoto, H., Akizuki, M., Sasazuki, T., Nishikimi, N., Ouchi, H., Kobayashi, Y., Numano, F., Kimura, A. Tissue Antigens (2001) [Pubmed]
  3. The altered hemorheologic parameters in thromboangiitis obliterans: a new insight. Bozkurt, A.K., Koksal, C., Ercan, M. Clin. Appl. Thromb. Hemost. (2004) [Pubmed]
  4. Effects of transvenous regional guanethidine block in the treatment of critical finger ischemia. Stümpflen, A., Ahmadi, A., Attender, M., Gschwandtner, M., Hofmann, S., Maca, T., Schnürer, G., Minar, E. Angiology. (2000) [Pubmed]
  5. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Fiessinger, J.N., Schäfer, M. Lancet (1990) [Pubmed]
  6. The role of cocaine in the etiology of Buerger disease is questionable. Bozkurt, A.K. Arch. Intern. Med. (2001) [Pubmed]
  7. Controlled trial of propranolol in intermittent claudication. Reichert, N., Shibolet, S., Adar, R., Gafni, J. Clin. Pharmacol. Ther. (1975) [Pubmed]
  8. Is there a role for genetic polymorphism of C677T methylenetetrahydrofolate reductase (MTHFR) in Buerger's disease? Kawasaki, T., Fujimura, H., Kakinoki, E., Uemichi, A., Miyata, T. Thromb. Haemost. (2000) [Pubmed]
  9. Successful treatment of digital ulceration in Buerger's disease with nicotine chewing gum. Kawabata, H., Kanekura, T., Gushi, A., Shimada, H., Higo, A., Usuki, K., Kanzaki, T. Br. J. Dermatol. (1999) [Pubmed]
  10. Amounts of coronary arterial luminal narrowing and composition of the material causing the narrowing in Buerger's disease. Mautner, G.C., Mautner, S.L., Lin, F., Roggin, G.M., Roberts, W.C. Am. J. Cardiol. (1993) [Pubmed]
  11. Enhanced platelet response to serotonin in Buerger's disease. Pietraszek, M.H., Choudhury, N.A., Koyano, K., Sakaguchi, S., Kamiya, T., Urano, T., Takada, Y., Takada, A. Thromb. Res. (1990) [Pubmed]
  12. The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Rydzewski, A., Urano, T., Hachiya, T., Kaneko, H., Baba, S., Takada, Y., Takada, A. Thromb. Res. (1996) [Pubmed]
  13. Evidence for an HLA-linked resistance gene in Buerger's disease. de Moerloose, P., Jeannet, M., Mirimanoff, P., Bouvier, C.A. Tissue Antigens (1979) [Pubmed]
  14. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Morishita, R., Aoki, M., Hashiya, N., Makino, H., Yamasaki, K., Azuma, J., Sawa, Y., Matsuda, H., Kaneda, Y., Ogihara, T. Hypertension (2004) [Pubmed]
  15. Lipid metabolism of the arterial wall in thromboangiitis obliterans (Buerger's disease). Horsch, A.K. Virchows Archiv. A, Pathological anatomy and histology. (1975) [Pubmed]
  16. Serotonin as a factor involved in pathophysiology of thromboangiitis obliterans. Pietraszek, M.H., Choudhury, N.A., Baba, S., Sakaguchi, S., Hachiya, T., Urano, T., Takada, Y., Takada, A. International angiology : a journal of the International Union of Angiology. (1993) [Pubmed]
  17. The influence of balneotherapy on T-cell populations and direct lymphocytotoxicity in patients with vascular disorders of lower limbs. Ortyl, W., Turowski, G., Zubel, M. Materia medica Polona. Polish journal of medicine and pharmacy. (1991) [Pubmed]
  18. Serum concentrations of vascular endothelial growth factor and monocyte-colony stimulating factor in peripheral arterial disease. Matsui, K., Yoshioka, T., Murakami, Y., Takahashi, M., Shimada, K., Ikeda, U. Circ. J. (2003) [Pubmed]
  19. Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease). Choudhury, N.A., Pietraszek, M.H., Hachiya, T., Baba, S., Sakaguchi, S., Takada, Y., Takada, A. Thromb. Res. (1992) [Pubmed]
  20. Buerger's disease involving the celiac artery. Sobel, R.A., Ruebner, B.H. Hum. Pathol. (1979) [Pubmed]
  21. Study of anti-neutrophil cytoplasmic antibodies in patients with thromboangiitis obliterans (Buerger's disease). Halacheva, K.S., Manolova, I.M., Petkov, D.P., Andreev, A.P. Scand. J. Immunol. (1998) [Pubmed]
  22. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. Isner, J.M., Baumgartner, I., Rauh, G., Schainfeld, R., Blair, R., Manor, O., Razvi, S., Symes, J.F. J. Vasc. Surg. (1998) [Pubmed]
WikiGenes - Universities